SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979;20: 72937.
  • 2
    Forsgren L. Epidemiology of intractable epilepsy in adults. In: JohannessenSI, GramL, SillanpaaM, et al., eds. Intractable epilepsy. Petersfield , UK : Wrightson Biomedical Publishing, 1995: 2540.
  • 3
    Cockerell OC, Johnson AL, Sander JWAS, et al. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346: 1404.
  • 4
    Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342: 3149.
  • 5
    Sperling MR. The consequences of uncontrolled epilepsy. CNS Spectrums 2004;9: 98101, 106–9.
  • 6
    Schmidt D. Prognosis of chronic epilepsy with complex partial seizures. J Neurol Neurosurg Psychiatry 1984;47: 12748.
  • 7
    Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999;34: 10922.
  • 8
    Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition? Seizure 2002;11: 7784.
  • 9
    Löscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 2002;23: 1138.
  • 10
    French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62: 126173.
  • 11
    National Association of Epilepsy Centers. Recommended guidelines for the diagnosis and treatment in specialized epilepsy centers. Epilepsia 1990;31(suppl 1):S112.
  • 12
    Berg AT, Shinnar S, Levy SR, et al. Early development of intractable epilepsy in children: a prospective study. Neurology 2001;56: 144552.
  • 13
    Elger CE. Pharmacoresistance: modern concept and basic data derived from human brain tissue. Epilepsia 2003;44(suppl 5):915.
  • 14
    Perucca E. Pharmacoresistance in epilepsy: how should it be defined? CNS Drugs 1998;10: 1719.
  • 15
    Berg AT. Understanding the delay before epilepsy surgery: who develops intractable focal epilepsy and when? CNS Spectrums 2004;9: 13644.
  • 16
    Schmidt D. Medical intractability in partial epilepsies. In: HLüders, ed. Epilepsy surgery. New York : Raven Press, 1991: 8390.
  • 17
    Sillanpää M, Jalava M, Shinnar S. Epilepsy syndromes in patients with childhood-onset seizures in Finland. Pediatr Neurol 1999;21: 5337.
  • 18
    Spencer SS. When should temporal-lobe epilepsy be treated surgically? Lancet Neurol 2002;1: 37582.
  • 19
    Holmes GL. Epidemiology and clinical mechanisms of drug resistance in epilepsy: new horizons in the development of antiepileptic drugs: the search for new targets: a conference review. Epilepsy Res 2004;60: 77159.
  • 20
    Brodie MJ. Glasgow outcome studies: new horizons in the development of antiepileptic drugs: the search for new targets. a conference review. Epilepsy Res 2004;60: 967
  • 21
    Stephen LJ, Kwan P, Brodie MJ. Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia 2001;42: 35762.
  • 22
    Kim WJ, Park SC, Lee SJ, et al. The prognosis for control of seizures with medications in patients with MRI evidence for mesial temporal sclerosis. Epilepsia 1999;40: 2903.
  • 23
    Kumlien E, Doss RC, Gates JR. Treatment outcome in patients with mesial temporal sclerosis. Seizure 2002;11: 4137.
  • 24
    Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51: 125662.
  • 25
    Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001;42: 51524.
  • 26
    Löscher W, Schmidt D. New horizons in the development of antiepileptic drugs: the search for new targets. Epilepsy Res 2004;60: 77159.
  • 27
    Marson A. Should we start early therapy? Yes or no? And why? Eur J Neurol 2004;11(suppl 2):3334.
  • 28
    Hauser WA. The natural history of drug resistant epilepsy: epidemiological considerations. Epilepsy Res 1992;suppl 5: 258.
  • 29
    Shorvon SD, Sander JWAS. Temporal patterns of remission and relapse in seizures of patients with epilepsy. In: SchmidtD, MorselliPL, eds. Intractable epilepsy: experimental and clinical aspects. New York : Raven Press, 1986: 324.
  • 30
    Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001;42: 125560.
  • 31
    Camfield PR, Camfield CS, Gordon K, et al. If a first antiepileptic drug fails to control a child's epilepsy, what are the chances of success with the next drug? J Pediatr 1997;131: 8214.
  • 32
    Berg AT, Langfitt J, Shinnar S, et al. How long does it take for partial epilepsy to become intractable? Neurology 2003;60: 18690.
  • 33
    Engel J. Update on surgical treatment of the epilepsies. In: EngelJ, ed. Surgical treatment of epilepsies. New York : Raven Press, 1987: 3248.
  • 34
    Sutula TP, Hagen J, Pitkanen A. Do epileptic seizures damage the brain? Curr Opin Neurol 2003;16: 18995.
  • 35
    Briellmann R, Berkovic S, Syngeniotis A, et al. Seizure-associated hippocampal volume loss: a longitudinal magnetic resonance study of temporal lobe epilepsy. Ann Neurol 2002;51: 6414.
  • 36
    Fuerst D, Shah A, Watson C. Hippocampal sclerosis is a progressive disorder: a longitudinal volumetric MRI study. Ann Neurol 2003;53: 4136.
  • 37
    Liu RSN, Lemieux L, Bell GS, et al. Progressive neocortical damage in epilepsy. Ann Neurol 2003;53: 31224.
  • 38
    Helmstaedter C. Effects of chronic epilepsy on declarative memory systems. Prog Brain Res 2002;135: 43953.
  • 39
    Engel J, Wieser H-G. Mesial temporal lobe epilepsy. In: EngelJ, PedleyTA, eds. Epilepsy: a comprehensive textbook. Philadelphia : Lippincott-Raven, 1997: 241726.
  • 40
    Schmidt D, Löscher W. Uncontrolled epilepsy emerging following discontinuation of antiepileptic drugs in seizure free patients: a review of current clinical experience. Acta Neurol Scand 2005 (in press).
  • 41
    Medical Research Council AED Withdrawal Study Group. Randomised study in antiepileptic drug withdrawal in patients in remission. Lancet 1991;337: 117580.
  • 42
    French JA, Kugler AR, Robbins JL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60: 16317.
  • 43
    Löscher W. New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 1998;342: 113.
  • 44
    Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5: 55364.
  • 45
    Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004;101: 98616.
  • 46
    Vreugdenhil M, Vanveelen CWM, Vanrijen PC, et al. Effect of valproic acid on sodium currents in cortical neurons from patients with pharmaco-resistant temporal lobe epilepsy. Epilepsy Res 1998;32: 30920.
  • 47
    Remy S, Gabriel S, Urban BW, et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 2003;53: 46979.
  • 48
    Vreugdenhil M, Wadman WJ. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia 1999;40: 151222.
  • 49
    Remy S, Urban BW, Elger CE, et al. Anticonvulsant pharmacology of voltage-gated Na+ channels in hippocampal neurons of control and chronically epileptic rats. Eur J Neurosci 2003;17: 264858.
  • 50
    Ellerkmann RK, Remy S, Chen J, et al. Molecular and functional changes in voltage-dependent Na(+) channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neuroscience 2003;119: 32333.
  • 51
    Catterall WA. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv Neurol 1999;79: 44156.
  • 52
    Isom LL. Beta subunits: players in neuronal hyperexcitability? Novartis Found Symp 2002;241: 12438.
  • 53
    Löscher W. Animal models of epilepsy and epileptic seizures. In: EadieMJ, VajdaF, eds. Antiepileptic drugs: handbook of experimental pharmacology. Berlin : Springer, 1999: 1962.
  • 54
    Leite JP, Cavalheiro EA. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res 1995;20: 93104.
  • 55
    Löscher W. Animal models of drug resistant epilepsy. In: LingV, ed. Mechanisms of drug resistance in epilepsy: lessons from oncology. Chichester : Wiley, 2002: 14958.
  • 56
    Glien M, Brandt C, Potschka H, et al. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 2002;43: 3507.
  • 57
    Jeub M, Beck H, Siep E, et al. Effect of phenytoin on sodium and calcium currents in hippocampal CA1 neurons of phenytoin-resistant kindled rats. Neuropharmacology 2002;42: 10716.
  • 58
    Mulley JC, Scheffer IE, Petrou S, et al. Channelopathies as a genetic cause of epilepsy. Curr Opin Neurol 2003;16: 1716.
  • 59
    Steinlein OK. Genes and mutations in human idiopathic epilepsy. Brain Dev 2004;26: 2138.
  • 60
    Depondt C, Weale M, Smith A, et al. Association study of the SCN1A gene in epilepsy and drug responsiveness. Epilepsia 2002;43(suppl 8):39.
  • 61
    Möhler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002;300: 28.
  • 62
    Rudolph U, Möhler H. Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev Pharmacol Toxicol 2004;44: 47598.
  • 63
    Kamphuis W, De Rijk TC, Lopes da Silva FH. GABAA receptor beta 1-3 subunit gene expression in the hippocampus of kindled rats. Neurosci Lett 1994;174: 58.
  • 64
    Kokaia M, Pratt GD, Elmer E, et al. Biphasic differential changes of GABAA receptor subunit mRNA levels in dentate gyrus granule cells following recurrent kindling-induced seizures. Brain Res Mol Brain Res 1994;23: 32332.
  • 65
    Kamphuis W, De Rijk TC, Lopes da Silva FH. Expression of GABAA receptor subunit mRNAs in hippocampal pyramidal and granular neurons in the kindling model of epileptogenesis: an in situ hybridization study. Brain Res Mol Brain Res 1995;31: 3347.
  • 66
    Brooks-Kayal AR, Shumate MD, Jin H, et al. Selective changes in single cell GABAA receptor subunit expression and function in temporal lobe epilepsy. Nat Med 1998;4: 116672.
  • 67
    Nusser Z, Hajos N, Somogyi P, et al. Increased number of synaptic GABA(A) receptors underlies potentiation at hippocampal inhibitory synapses. Nature 1998;395: 1727.
  • 68
    Sperk G, Schwarzer C, Tsunashima K, et al. Expression of GABA(A) receptor subunits in the hippocampus of the rat after kainic acid-induced seizures. Epilepsy Res 1998;32: 12939.
  • 69
    Brooks-Kayal AR, Shumate MD, Jin H, et al. Human neuronal gamma-aminobutyric acid(A) receptors: coordinated subunit mRNA expression and functional correlates in individual dentate granule cells. J Neurosci 1999;19: 83128.
  • 70
    Fritschy JM, Kiener T, Bouilleret V, et al. GABAergic neurons and GABA(A)-receptors in temporal lobe epilepsy. Neurochem Int 1999;34: 4355.
  • 71
    Bouilleret V, Loup F, Kiener T, et al. Early loss of interneurons and delayed subunit-specific changes in GABA(A)-receptor expression in a mouse model of mesial temporal lobe epilepsy. Hippocampus 2000;10: 30524.
  • 72
    Redecker C, Luhmann HJ, Hagemann G, et al. Differential downregulation of GABAA receptor subunits in widespread brain regions in the freeze-lesion model of focal cortical malformations. J Neurosci 2000;20: 504553.
  • 73
    Meguro R, Lu ZW, Gavrilovici C, et al. Static, transient and permanent organisation of GABAA receptor expression in calbindin positive interneurons in response to amygdala kindled seizures. J Neurochem 2004;91: 14454.
  • 74
    Loup F, Wieser HG, Yonekawa Y, et al. Selective alterations in GABAA receptor subtypes in human temporal lobe epilepsy. J Neurosci 2000;20: 540119.
  • 75
    Coulter DA. Epilepsy-associated plasticity in gamma-aminobutyric acid receptor expression, function, and inhibitory synaptic properties. Int Rev Neurobiol 2001;45: 23752.
  • 76
    Coulter DA. Mossy fiber zinc and temporal lobe epilepsy: pathological association with altered “epileptic” gamma-aminobutyric acid A receptors in dentate granule cells. Epilepsia 2000;41(suppl 6):S969.
  • 77
    Cohen AS, Lin DD, Quirk GL, et al. Dentate granule cell GABA(A) receptors in epileptic hippocampus: enhanced synaptic efficacy and altered pharmacology. Eur J Neurosci 2003;17: 160716.
  • 78
    Kapur J, Macdonald RL. Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 1997;17: 753240.
  • 79
    Macdonald RL, Kapur J. Acute cellular alterations in the hippocampus after status epilepticus. Epilepsia 1999;40: S920.
  • 80
    Jones DM, Esmaeil N, Maren S, et al. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res 2002;50: 30112.
  • 81
    Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal. Br J Pharmacol 2002;136: 65972.
  • 82
    Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004;10: 1295312.
  • 83
    Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55: 329.
  • 84
    Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 2003;55: 83105.
  • 85
    Tishler DM, Weinberg KT, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36: 16.
  • 86
    Sisodiya SM, Heffernan J, Squier MV. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 1999;10: 343741.
  • 87
    Sisodiya SM, Lin W-R, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125: 2231.
  • 88
    Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42: 15016.
  • 89
    Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003;118: 41729.
  • 90
    Aronica E, Gorter JA, Ramkema M, et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2004;45: 44151.
  • 91
    Zhang L, Ong WY, Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Exp Brain Res 1999;126: 50916.
  • 92
    Seegers U, Potschka H, Löscher W. Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res 2002;51: 25768.
  • 93
    Volk HA, Burkhardt K, Potschka H, et al. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004;123: 7519.
  • 94
    Volk HA, Potschka H, Löscher W. Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res 2004;58: 6779.
  • 95
    Potschka H, Volk HA, Löscher W. Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. Neuroreport 2004;15: 165761.
  • 96
    Sisodiya SM, Lin WR, Squier MV, et al. Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 2001;357: 423.
  • 97
    Sisodiya SM, Martinian L, Scheffer GL, et al. Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia 2003;44: 138896.
  • 98
    Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005;46: 22435.
  • 99
    Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301: 714.
  • 100
    Marroni M, Marchi N, Cucullo L, et al. Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy. Curr Drug Targets 2003;4: 297304.
  • 101
    Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 2003;16: 197201.
  • 102
    Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette (ABC) gene family. NeuroRx 2005;2: 8698.
  • 103
    Edwards RH. Drug delivery via the blood-brain barrier. Nat Neurosci 2001;4: 2212.
  • 104
    Marchi N, Hallene KL, Kight KM, et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med 2004;2: 37.
  • 105
    Potschka H, Löscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001;42: 123140.
  • 106
    Potschka H, Löscher W. Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. Neuroreport 2001;12: 23879.
  • 107
    Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002;22: 58339.
  • 108
    Potschka H, Fedrowitz M, Löscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003;306: 12431.
  • 109
    Potschka H, Fedrowitz M, Löscher W. P-Glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001;12: 355760.
  • 110
    Sills GJ, Kwan P, Butler E, et al. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav 2002;3: 42732.
  • 111
    Frey H-H, Löscher W. Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology 1978;17: 63742.
  • 112
    Huai-Yun H, Secrest DT, Mark KS, et al. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun 1998;243: 81620.
  • 113
    Gibbs JP, Adeyeye MC, Yang Z, et al. Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport. Epilepsy Res 2004;58: 5366.
  • 114
    Potschka H, Fedrowitz M, Löscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002;327: 1736.
  • 115
    Potschka H, Fedrowitz M, Löscher W. Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats. Epilepsia 2003;44: 147986.
  • 116
    Luer MS, Hamani C, Dujovny M, et al. Saturable transport of gabapentin at the blood-brain barrier. Neurol Res 1999;21: 55962.
  • 117
    Potschka H, Baltes S, Löscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res 2004;58: 8591.
  • 118
    Borst P, Evers R, Kool M, et al. The multidrug resistance protein family. Biochim Biophys Acta 1999;1461: 34757.
  • 119
    Zhang Y, Schuetz JD, Elmquist WF, et al. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther 2004;311: 44955.
  • 120
    Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348: 14428.
  • 121
    Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004;26: 1805.
  • 122
    Ishikawa T, Onishi Y, Hirano H, et al. Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol Pharm Bull 2004;27: 93948.
  • 123
    Hoffmeyer S, Burk O, Von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97: 34738.
  • 124
    Tan NC, Heron SE, Scheffer IE, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004;63: 10902.
  • 125
    Zimprich F, Sunder-Plassmann R, Stogmann E, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 2004;63: 10879.
  • 126
    Weiss J, Kerpen CJ, Lindenmaier H, et al. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 2003;307: 2627.
  • 127
    Owen A, Pirmohamed M, Tettey JN, et al. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001;51: 3459.
  • 128
    Cornford EM, Oldendorf WH. Epilepsy and the blood-brain barrier. Adv Neurol 1986;44: 787812.
  • 129
    Duncan R, Todd N. Epilepsy and the blood-brain barrier. Br J Hosp Med 1991;45: 324.
  • 130
    Cornford EM. Epilepsy and the blood brain barrier: endothelial cell responses to seizures. Adv Neurol 1999;79: 84562.
  • 131
    Hauser WA, Lee JR. Do seizures beget seizures? In: Do seizures damage the brain? Prog Brain Res 2002;135: 2159.
  • 132
    Berg A, Shinnar S. Do seizures beget seizures? An assessment of the clinical relevance in humans. J Clin Neurophysiol 1997;14: 10110.
  • 133
    MacDonald BK, Johnson AL, Goodridge DM, et al. Factors predicting prognosis of epilepsy after presentation with seizures. Ann Neurol 2000;48: 83341.
  • 134
    Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential p-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 2004;38: 16314.
  • 135
    Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003;10: 15965.
  • 136
    Löscher W, Schmidt D. New horizons in the development of antiepileptic drugs. Epilepsy Res 2002;50: 316.
  • 137
    Frey H-H, Fröscher W, Koella WP, et al. Tolerance to beneficial and adverse effects of antiepileptic drugs. New York : Raven Press, 1986.
  • 138
    Boggs JG, Nowack WJ, Drinkard CR. Analysis of the “honey moon effect” in adult epilepsy patients. Epilepsia 2000;41(suppl 7):222.
  • 139
    Lowenstein DH. Recent advances related to basic mechanisms of epileptogenesis. Epilepsy Res Suppl 1996;11: 4560.
  • 140
    Nadler JV. The recurrent mossy fiber pathway of the epileptic brain. Neurochem Res 2003;28: 164958.
  • 141
    Faingold CL. Emergent properties of CNS neuronal networks as targets for pharmacology: application to anticonvulsant drug action. Prog Neurobiol 2004;72: 5585.
  • 142
    Proper EA, Hooglan G, Kappen SM, et al. Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain 2003;125: 3243.
  • 143
    Löscher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res 1994;17: 95134.
  • 144
    Elsinga PH, Hendrikse NH, Bart J, et al. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Design 2004;10: 1493503.
  • 145
    Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004;5: 62735.
  • 146
    Schmidt D. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res 2002;50: 2132.
  • 147
    Pitkänen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 2002;1: 17381.
  • 148
    Walker MC, White HS, Sander JW. Disease modification in partial epilepsy. Brain 2002;125: 193750.
  • 149
    Schmidt D, Rogawski MA. New strategies for the development of antiepileptic drugs that prevent the development or progression of the epileptic progress. Epilepsy Res 2002;50: 718.
  • 150
    Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000;12: 4508.
  • 151
    Litman T, Druley TE, Stein WD, et al. New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58: 93159.